PPA
SAGE

Parametric Portfolio Associates’s Sage Therapeutics SAGE Stock Holding History

Parametric Portfolio Associates’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$2.07M Sell
62,590
-61,479
-50% -$2.31M ﹤0.01% 2407
2021
Q4 		$5.28M Sell
124,069
-21,757
-15% -$911K ﹤0.01% 1829
2021
Q3 		$6.46M Sell
145,826
-33,293
-19% -$1.53M ﹤0.01% 1660
2021
Q2 		$10.2M Sell
179,119
-14,926
-8% -$1.06M 0.01% 1378
2021
Q1 		$14.5M Sell
194,045
-12,198
-6% -$1M 0.01% 1377
2020
Q4 		$17.8M Buy
206,243
+26,695
+15% +$1.97M 0.01% 1136
2020
Q3 		$11M Buy
179,548
+41,180
+30% +$2.09M 0.01% 1330
2020
Q2 		$5.75M Buy
138,368
+46,676
+51% +$1.69M ﹤0.01% 1778
2020
Q1 		$2.63M Buy
91,692
+54,421
+146% +$3.15M ﹤0.01% 2203
2019
Q4 		$2.69M Sell
37,271
-11,478
-24% -$1.41M ﹤0.01% 2492
2019
Q3 		$6.84M Buy
48,749
+1,087
+2% +$182K 0.01% 1776
2019
Q2 		$8.73M Buy
47,662
+11,323
+31% +$1.93M 0.01% 1570
2019
Q1 		$5.78M Buy
36,339
+13,131
+57% +$1.9M 0.01% 1877
2018
Q4 		$2.22M Buy
23,208
+598
+3% +$68.4K ﹤0.01% 2516
2018
Q3 		$3.19M Sell
22,610
-1,038
-4% -$160K ﹤0.01% 2367
2018
Q2 		$3.7M Buy
23,648
+27
+0.1% +$4.24K ﹤0.01% 2217
2018
Q1 		$3.81M Sell
23,621
-3,280
-12% -$557K ﹤0.01% 2130
2017
Q4 		$4.43M Buy
26,901
+5,204
+24% +$505K ﹤0.01% 2004
2017
Q3 		$1.35M Sell
21,697
-838
-4% -$65.8K ﹤0.01% 2851
2017
Q2 		$1.79M Sell
22,535
-2,041
-8% -$148K ﹤0.01% 2619
2017
Q1 		$1.75M Buy
24,576
+5,842
+31% +$342K ﹤0.01% 2533
2016
Q4 		$957K Sell
18,734
-5,781
-24% -$272K ﹤0.01% 2856
2016
Q3 		$1.13M Buy
24,515
+6,829
+39% +$278K ﹤0.01% 2726
2016
Q2 		$533K Sell
17,686
-3,857
-18% -$129K ﹤0.01% 3154
2016
Q1 		$691K Buy
21,543
+13,810
+179% +$486K ﹤0.01% 3157
2015
Q4 		$451K Buy
+7,733
New +$383K ﹤0.01% 3321

Other funds holding SAGE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Parametric Portfolio Associates's SAGE Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Sage Therapeutics (SAGE) stake by 50% in Q1 2022, selling an estimated $2.31M and leaving 62,590 shares worth $2.07M. The position accounts for ﹤0.01% of the portfolio, ranked #2407.

Parametric Portfolio Associates first reported a position in SAGE in Q4 2015 and has held it in 26 quarters since. The position peaked at $17.8M in Q4 2020. 212 funds tracked by Wall St. Rank hold SAGE as of Q1 2022.

  • Parametric Portfolio Associates held 62,590 shares of Sage Therapeutics worth $2.07M as of Q1 2022.
  • Parametric Portfolio Associates sold 61,479 Sage Therapeutics shares in Q1 2022, an estimated $2.31M.
  • Sage Therapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2407 holding.
  • Parametric Portfolio Associates first reported a position in Sage Therapeutics in Q4 2015 and has held it in 26 quarters since.
  • Parametric Portfolio Associates's Sage Therapeutics position peaked at $17.8M in Q4 2020.
  • 212 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.